Stock Events

Aytu BioPharma 

$2.83
0
+$0+0% Friday 17:29

Statistics

Day High
2.83
Day Low
2.83
52W High
3.5
52W Low
1.4
Volume
10
Avg. Volume
623
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

15MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-3.6
-2.41
-1.23
-0.04
Expected EPS
-0.64
Actual EPS
-0.52

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A8M.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a global pharmaceutical company that competes with Aytu BioPharma in the development and marketing of medications in various therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson operates in the pharmaceutical sector, offering products that could directly compete with Aytu BioPharma's portfolio, especially in pediatrics and other health areas.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie competes in similar therapeutic areas as Aytu BioPharma, including testosterone replacement therapy and other pharmaceuticals.
Merck &
MRK
Mkt Cap318.55B
Merck is a leading pharmaceutical company with a broad product line that can compete with Aytu BioPharma's offerings in various health conditions.
Lilly(Eli) &
LLY
Mkt Cap814.94B
Eli Lilly and Company is involved in the development and marketing of pharmaceutical products that could compete with Aytu BioPharma, especially in the areas of men's health.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Aytu BioPharma in various therapeutic areas.
Novartis
NVS
Mkt Cap232.42B
Novartis is a global healthcare company that offers products which could compete with Aytu BioPharma in several therapeutic areas, including pediatrics.
GSK
GSK
Mkt Cap81.55B
GlaxoSmithKline is a global healthcare company with a wide range of pharmaceutical products that could compete with Aytu BioPharma, especially in respiratory and pediatric medicines.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb is a global biopharmaceutical company with a diverse portfolio of products that could compete with Aytu BioPharma in various therapeutic areas.

About

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Show more...
CEO
Mr. Joshua R. Disbrow
Employees
164
Country
United States
ISIN
US0547548588
WKN
000A2QJRT

Listings